13D Filings
Alaunos Therapeutics, Inc.
TCRT
Initial Filing
Ownership

5.09%

Total Shares

83,500

Issuer CIK

1107421

CUSIP

98973P309

Event Date

May 11, 2025

Accepted

May 14, 2025, 02:59 PM

Reporting Persons (2)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
PMGC CAPITAL LLC
Other
5.09%83,500083,500
PMGC Holdings Inc.
CO
5.09%83,500083,500
Disclosure Items (7)

Security Title

Common Stock

Issuer Name

Alaunos Therapeutics, Inc.

Issuer Address

2617 Bissonnet, Suite 233,, Houston, TX, 77005

Filing Persons

This Schedule 13D is filed on behalf of PMGC Capital LLC ("PMGC LLC"). PMGC Holdings Inc. ("PMGC Holdings") is the sole member of PMGC LLC and exercises voting and dispositive control over the common stock held in the name of PMGC LLC.

Business Address

The principal business address of PMGC LLC is 120 Newport Center Drive, Ste. 249, Newport Beach, California 92660.

Principal Occupation

PMGC LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. PMGC LLC is a wholly-owned subsidiary of PMGC Holdings.

Convictions

During the last five years, neither PMGC LLC nor PMGC Holdings has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Citizenship

PMGC LLC is organized under the laws of Nevada.

The aggregate purchase price of the 83,500 shares of Common Stock beneficially owned by PMGC LLC was approximately $217,094.38. PMGC LLC used its working capital as the source of funds to purchase these shares.

PMGC LLC acquired shares of Alaunos Therapeutics, Inc.'s (the "Issuer") common stock based on its belief that these common stock represent an attractive investment opportunity. The following information may be deemed pertinent. PMGC Capital intends to engage constructively with the Issuer's management and board of directors to explore strategic opportunities, including potential mergers, acquisitions or partnerships. Depending on its assessment of various factors, PMGC LLC may, from time to time, modify its present intention as stated in this Item 4. Other than as described herein, or as described under Item 5 below, PMGC LLC does not currently have plans or proposals that relate to or would result in any of the transactions involving the Issuer described in subparagraphs (a) through (j) of Item 4 of Schedule 13D (although PMGC LLC may from time to time consider pursuing or proposing any such transactions and, in that connection, may discuss, evaluate and/or pursue any such transactions with their respective advisors, the Issuer or other persons).

Percentage of Class

PMGC LLC beneficially owns 83,500 shares of common stock, which represents 5.09295% of the Issuer's common stock, based on 1,639,521 issued and outstanding shares of the Issuer as of May 5, 2025, as reported in its Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission on May 9, 2025. PMGC Inc. is the sole member of PMGC LLC and exercises voting and dispositive control over the Issuer's common stock held in the name of PMGC LLC.

Number of Shares

PMGC LLC beneficially owns 83,500 shares of the Issuer's common stock and exercises voting and dispositive control over such common stock. PMGC Holdings is the sole member of PMGC LLC and exercises voting and dispositive control over the common stock held in the name of PMGC LLC.

Transactions

Between May 2, 2025 and May 12, 2025, PMGC LLC purchased, on the open market, 83,500 shares of the the Issuer's common stock at prices ranging between $2.49 to $2.99.

Shareholders

Not applicable.

Date of 5% Ownership

Not applicable.

Joint Filing Agreement between PMGC LLC and PMGC Holdings dated May 14, 2025.

See Joint Filing Agreement filed as Exhibit 99.1.